glp 1 agonist oral drugs New GLP-1 Guidelines for Type 2 Diabetes in 2025 GLP-1 Agonists: A Comprehensive Overview
Description
The first factor identified was gastric inhibitory polypeptide (GIP), which was thought to increase glucose-stimulated insulin secretion
Supriya Rao, M.D., medical director of the obesity medical program at Tufts Universitys Lowell General Hospital in Lowell, Massachusetts
M.MarksS.HollandJ.OttawayN.SmileyD.DimarchiR.et al
McComsey at Case Western Reserve University
Weight Loss and Mechanical Unloading : The most significant factor affecting bone density in patients taking GLP-1 medications is likely the substantial weight loss these agents produce
